Histidine

Histidine

SCHEMBL388563

NC(Cc1c[nH]cn1)C(=O)O.OO

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 3/20 0.47
CYP3A4 P08684 2/20 0.47
CYP1A2 P05177 1/20 0.46
PKM P14618 2/20 0.43
ALPI P09923 1/20 0.43
PTGS1 P23219 1/20 0.43
XIAP P98170 1/20 0.43
GRIA2 P42262 5/20 0.41
GRIA1 P42261 4/20 0.41
GRIA3 P42263 4/20 0.41
GRIA4 P48058 4/20 0.41
HSD17B10 Q99714 2/20 0.40
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 2/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 2/20 0.40
BLM P54132 2/20 0.40
PMP22 Q01453 2/20 0.40
KMT2A Q03164 2/20 0.40
HIF1A Q16665 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Histidine SCHEMBL8316642 1.00 SLC7A5 (0.47) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL8080341 1.00 SLC7A5 (0.47) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL388561 1.00 SLC7A5 (0.47) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL18824897 1.00 SLC7A5 (0.47) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL995910 1.00 SLC7A5 (0.47) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL3258 1.00 SLC7A5 (0.47) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL163443 1.00 SLC7A5 (0.47) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL3259 1.00 SLC7A5 (0.47) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL163442 1.00 SLC7A5 (0.47) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL29500208 1.00 SLC7A5 (0.47) SLC7A5CYP3A4CYP1A2PKMALPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2252333-A2 GAS BASED WOUND AND TISSUE THERAPEUTICS Oxygen Biotherapeutics, Inc. (US) 2010-11-24 EP claimed
WO-2009102487-A2 GAS BASED WOUND AND TISSUE THERAPEUTICS OXYGEN BIOTHERAPEUTICS, INC. (US) 2009-08-20 WO claimed
US-20150231177-A1 Methods and Compositions for Controlled and Sustained Production and Delivery of Peroxides and/or Oxygen for Biological and Industrial Applications VIRGINIA COMMONWEALTH UNIVERSITY (US) 2015-08-20 US disclosed
US-20130289471-A1 GAS BASED WOUND AND TISSUE THERAPEUTICS VIRGINIA COMMONWEALTH UNIVERSITY (US) 2013-10-31 US disclosed
US-20120207793-A1 Methods and Compositions for Controlled and Sustained Production and Delivery of Peroxides and/or Oxygen for Biological and Industrial Applications VIRGINIA COMMONWEALTH UNIVERSITY 2012-08-16 US disclosed
US-20120184898-A1 GAS BASED WOUND AND TISSUE THERAPEUTICS TENAX THERAPEUTICS, INC 2012-07-19 US disclosed
US-8101117-B2 Controlled gas pore formers in extruded ware CORNING, INCORPORATED (US) 2012-01-24 US disclosed
EP-2252333-A2 GAS BASED WOUND AND TISSUE THERAPEUTICS Oxygen Biotherapeutics, Inc. (US) 2010-11-24 EP disclosed
US-20090298667-A1 Controlled Gas Pore Formers in Extruded Ware CORNING INCORPORATED 2009-12-03 US disclosed
WO-2009102487-A2 GAS BASED WOUND AND TISSUE THERAPEUTICS OXYGEN BIOTHERAPEUTICS, INC. (US) 2009-08-20 WO disclosed
US-20090202617-A1 Gas based wound and tissue therapeutics TENAX THERAPEUTICS, INC 2009-08-13 US disclosed
US-20090169630-A1 Methods and Compositions for Controlled and Sustained Production and Delivery of Peroxides and/or Oxygen for Biological and Industrial Applications VIRGINIA COMMONWEALTH UNIVERSITY 2009-07-02 US disclosed
CN-101443272-A Methods and compositions for controlled and sustained generation and delivery of peroxides UNIV VIRGINIA COMMONWEALTH (US) 2009-05-27 CN disclosed
EP-2024287-A1 METHODS AND COMPOSITIONS FOR CONTROLLED AND SUSTAINED PRODUCTION AND DELIVERY OF PEROXIDES Virginia Commonwealth University (US) 2009-02-18 EP disclosed
WO-2009006586-A2 SELF-CONTAINED OXYGEN GENERATING AND BREATHING SYSTEMS VIRGINIA COMMONWEALTH UNIVERSITY (US) 2009-01-08 WO disclosed
WO-2007134304-A1 METHODS AND COMPOSITIONS FOR CONTROLLED AND SUSTAINED PRODUCTION AND DELIVERY OF PEROXIDES VIRGINIA COMMONWEALTH UNIVERSITY (US) 2007-11-22 WO disclosed
EP-0409612-A1 Histidine-hydrogen peroxide adduct and process for preparing same TOKAI DENKA KOGYO KABUSHIKI KAISHA (JP) 1991-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090202617-A1 Gas based wound and tissue therapeutics PGF, FGF2, FGF1 SLC7A5 4142/4885CYP3A4 3801/4885CYP1A2 1839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.